Latest Fda Approved Drugs Information Systems

The Food and Drug Administration (FDA) and inform the public that have been identified to test positive for antibodies against JC (JCV) as a risk factor for HIV leukoencephalopathy progressive multifocal (PML).  PML is an inflammation of the brain are rare but serious associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis (MS) or Crohn's disease. It should be that the risks and benefits of continuing treatment with Tysabri be carefully considered in patients who are found to be anti-JCV antibodies of the positive and you have one or more of the other risk factors known to the PML.  Patients who suffer from all the three known risk factors have estimated the risk of PML of 11/1 for users, 000.  Risk factors are: The presence of antibodies against JCV. Longer duration of treatment Tysabri, especially after 2 years. Before treatment with immunosuppressive drugs (for example, mitoxantrone, azathioprine, methotrexate, cyclophosphamide, or inhibition mofet

U.S. Food   and Drug Administration   today   approved   Inlyta (axitinib) for the treatment of   patients with   advanced   kidney cancer   ( renal cell carcinoma ) and those who   did not respond to   another drug   for this type of   cancer. Renal cell carcinoma   is a type of   kidney cancer   that starts   in the lining of   very   small tubes   in the kidneys.   Inlyta   works by blocking certain proteins   called   kinases   that play   a role in   tumor growth and cancer progression .   Inlyta   is a pill   that patients   take   twice a day.

January 26, 2012 - Men are more at risk for mild cognitive impairment, a new study shows.  The results were amazing, we refer to the investigators, because women generally have higher rates of dementia. "We expect to see a similar proportion of mild cognitive impairment in men and women," said lead researcher Gemma Roberts, MBChB, of the Mayo Clinic in Rochester, Minnesota, Medscape Medical News. The results, published online January 25 in the journal Neurology, suggest that should determine the risk factors for memory loss by sex.  Researchers wonder whether there could be even sex-specific strategies to reduce risk.   Dr. Rosebud Roberts In an accompanying editorial, and commended Kenneth Rockwood, MD, of Dalhousie University and Queen Elizabeth Health Sciences Centre in Halifax, Nova Scotia, Canada, and work. "The study identified mild cognitive impairment and sub-retroactive, and not of diagnostic criteria retrofitted to talk."  Epidemiological data from the Ma

January 25, 2012 (Dallas, Texas) - An analysis of 18 Postgrad confirm that the differences in risk factor burden in middle-aged translate into large differences in the lives of the risk of heart disease and blood vessels [1]. "The current model when we think of prevention is to assess the risk over the next 10 years using something like the degree of risk Framingham ... and supposed to guide decision-making process," senior author Dr. Donald Lloyd-Jones (Northwestern University, said Chicago,  IL) heartwire.  "This approach is quite true, but this is an incomplete representation of the risk to our patients." New results of the project life risk of cardiovascular gathering, which was published in the January 26, 2012 issue of the New England Journal of Medicine, found that the risk in people in their 40s or 50S with risk factors and one or two, such as high blood pressure or high cholesterol in the blood ladders  sharply over their lives.  "So there is a separa

April 2, 2007 AstraZeneca reported positive results from Phase III trial, (Measuring the effects on the thickness and endothelial media: 1 OfRosuvastatin evaluation), of Crestor for the treatment of atherosclerosis.  He joined the 24-month, randomized, double-blind, placebo-controlled trial 984 shows, and hypercholesterolaemic subjects with low risk of coronary artery disease andevidence of sub-clinical atherosclerosis.  The results showed thatsubjects with Crestor 40 mg experienced 0.0014 mm / year and a decrease in endothelial thickness meanmaximum media carotid artery, a sign of the burden of atherosclerosis, compared to the evolution of 0.0131 mm / year for those on placebo (P ≤ 0. 0001).  Inaddition, Crestor reduced demonstrated 48.8% in LDL-C and 8 1.  0% increasein HDL-C (both p ≤ placebo versus 0.0001).  AstraZeneca plans to submit NDA and Crestor MAAfor in the treatment of atherosclerosis in the first half of 2007. Scios issued positive results of the second phase of the tri

January 18, 2012 (Oslo, Norway) - a normal level of blood pressure in healthy middle-aged man, the development of high risk prediction in elderly atrial fibrillation, a new study suggests [1]. The study was published online on January 17, 2012, high blood pressure, a Swedish group led by Dr. Eileen Grundvold (in Oslo, Norway University Hospital). They recruited the Group from 1972 to 1975 of 2014 healthy middle-aged men, they underwent a comprehensive clinical examination, including blood pressure measurement.  Up to 35 years of follow-up period, 270 people were found to have atrial fibrillation.  Late development in most of the life conditions, from a baseline average of 20 years of age. Blood pressure after adjustment of other risk factors, a quarter of the development of atrial fibrillation the risk estimates calculated on the basis.  The results show that the risk of atrial fibrillation in addition to those men in the baseline blood pressure, and a normal blood pressure levels